# Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

> **NCT04338620** · PHASE2 · UNKNOWN · sponsor: **Tang-Du Hospital** · enrollment: 94 (estimated)

## Conditions studied

- Non-small-cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** camrelizumab、albumin-bound paclitaxel and platinum
- **DRUG:** albumin-bound paclitaxel and platinum

## Key facts

- **NCT ID:** NCT04338620
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-07
- **Primary completion:** 2023-11
- **Final completion:** 2023-11-01
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2023-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04338620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04338620, "Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04338620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*